Related Experiment Video
Updated: Dec 30, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Targeting survivin sensitizes cervical cancer cells to radiation treatment
Jing Zhou1, Xiaojing Guo2, Weifen Chen2
1Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Abstract:
Survivin is an inhibitor of apoptosis protein that functions to inhibit apoptosis, promote proliferation, and enhance invasion. It is selectively up-regulated in many human tumors and implicated in cellular radiation response through its role in apoptosis, cell division, and DNA damage response. This study aimed to investigate the effect and mechanisms of targeting survivin radiosensitivity in cervical cancer C33A cells. Here, the authors designed a small interfering RNA (siRNA) or plasmid-based small hairpin RNA (shRNA) targeting survivin and tested its effects on radiosensitivity to ionizing radiation (IR) treatment of C33A cells in vitro, as well as on the tumorigenicity of C33A cells in nude mice in vivo. Transient transfection of survivin siRNA into C33A cells suppressed survivin expression, induced cell apoptosis and G2/M arrest and reduced cell proliferation, clone formation ability after IR, followed by p53 upregulated modulator of apoptosis (PUMA) upregulation. But, transient transfection of survivin siRNA alone has no significant effect on cell growth and apoptosis. To confirm that PUMA upregulation is necessary for survivin silencing -induced radiosensitivity to IR treatment, the effect of targeting PUMA in survivin sliencing cells was observed. The results showed that targeting PUMA in survivin sliencing cells rescued C33A cells' radioresistance. Furthermore, knocking down survivin expression combined with IR treatment significantly slowed tumor growth and promoted tumor cell apoptosis in C33A xenografted tumors. It was concluded that survivin played a role in radiotherapy resistance. Targeting survivin increased the radiosensitivity of C33A cells through induction of PUMA expression.
Insights
Targeting survivin, an apoptosis inhibitor, enhances cervical cancer cell radiosensitivity. This approach, by upregulating PUMA, overcomes resistance to ionizing radiation and slows tumor growth.
Area of Science:
- Molecular Biology
- Oncology
- Radiotherapy Research
Background:
- Survivin, an apoptosis inhibitor, is upregulated in tumors and affects radiation response.
- Cervical cancer cells exhibit radioresistance, necessitating strategies to enhance treatment efficacy.
Purpose of the Study:
- To investigate the effect of targeting survivin on radiosensitivity in cervical cancer cells.
- To elucidate the mechanisms by which survivin inhibition impacts radiosensitivity, focusing on PUMA.
Main Methods:
- Small interfering RNA (siRNA) and small hairpin RNA (shRNA) were used to target survivin in C33A cervical cancer cells.
- In vitro studies assessed radiosensitivity to ionizing radiation (IR), cell apoptosis, cell cycle arrest, and proliferation.
- In vivo studies evaluated the effect of survivin knockdown and IR on tumor growth in nude mice xenografts.
Main Results:
- Survivin suppression via siRNA induced apoptosis and G2/M arrest, reducing proliferation and clone formation post-IR.
- Survivin knockdown led to p53 upregulated modulator of apoptosis (PUMA) upregulation, which was crucial for radiosensitization.
- Combined survivin knockdown and IR treatment significantly inhibited tumor growth and increased apoptosis in vivo.
Conclusions:
- Survivin plays a significant role in radioresistance of cervical cancer cells.
- Targeting survivin enhances radiosensitivity by inducing PUMA expression, offering a potential therapeutic strategy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

